Can-Fite BioPharma Ltd. (CANF)

1.40
0.02 1.41
AMEX : Health Technology
Prev Close 1.42
Open 1.41
Day Low/High 1.38 / 1.42
52 Wk Low/High 1.12 / 2.75
Volume 60.56K
Avg Volume 53.80K
Exchange AMEX
Shares Outstanding 19.98M
Market Cap 26.65M
EPS -0.30
P/E Ratio 9.20
Div & Yield N.A. (N.A)
Prior To Phase II Liver Cancer Data Release Can-Fite Brings On Board An Oncologist Expert

Prior To Phase II Liver Cancer Data Release Can-Fite Brings On Board An Oncologist Expert

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced that Professor Josep Llovet, an experienced leader with deep...

Due To Patient Survival, Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

Due To Patient Survival, Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver, and inflammatory diseases, today provided an update on its Phase II clinical trial of...

Can-Fite To Present On Its Liver Cancer Drug Namodenoson At The NYC Oncology Investor Conference

Can-Fite To Present On Its Liver Cancer Drug Namodenoson At The NYC Oncology Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, today announced that its CEO, Dr.

Can-Fite CEO To Present As Expert Speaker On Namodenoson At NASH Summit Europe 2018

Can-Fite CEO To Present As Expert Speaker On Namodenoson At NASH Summit Europe 2018

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, today announced that its CEO, Dr.

Can-Fite To Present The Anti-Fibrogenic Effects Of Namodenoson At The Hepatic Fibrosis Conference Of The American Association For The Study Of Liver Diseases (AASLD)

Can-Fite To Present The Anti-Fibrogenic Effects Of Namodenoson At The Hepatic Fibrosis Conference Of The American Association For The Study Of Liver Diseases (AASLD)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced its poster presentation of the...

Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected By End Of Year

Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected By End Of Year

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial of...

Can-Fite Reports Second Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite Reports Second Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the three months...

Can-Fite BioPharma Announces Participation At The 20th Annual Global Investment Conference In New York City September 4-6, 2018

Can-Fite BioPharma Announces Participation At The 20th Annual Global Investment Conference In New York City September 4-6, 2018

Can-Fite BioPharma (CANF), today announced it will be featured as a presenting company at the 20 th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.

Can-Fite Announces Enrollment Of First Patient In Its Comfort™ Phase III Trial Of Piclidenoson In Psoriasis

Can-Fite Announces Enrollment Of First Patient In Its Comfort™ Phase III Trial Of Piclidenoson In Psoriasis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the first patient has been enrolled and dosed...

Can-Fite Receives From CMS Medical Venture Investment Limited $2,000,000 Upfront Payment As Part Of Development, Registration And Marketing Agreement For Piclidenoson And Namodenoson In China

Can-Fite Receives From CMS Medical Venture Investment Limited $2,000,000 Upfront Payment As Part Of Development, Registration And Marketing Agreement For Piclidenoson And Namodenoson In China

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has received its first payment of...

Can-Fite Signs Multi-Million Dollar Development And Distribution Agreement For Piclidenoson And Namodenoson In China With CMS Medical

Can-Fite Signs Multi-Million Dollar Development And Distribution Agreement For Piclidenoson And Namodenoson In China With CMS Medical

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has signed a License, Collaboration and...

Can-Fite Granted Australian And Chinese Patents For Erectile Dysfunction Drug

Can-Fite Granted Australian And Chinese Patents For Erectile Dysfunction Drug

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and...

Drugs With Mechanism Of Action Utilized By Namodenoson Are Recommended By Leading U.S. Researchers To Be Developed To Combat Liver Cancer

Drugs With Mechanism Of Action Utilized By Namodenoson Are Recommended By Leading U.S. Researchers To Be Developed To Combat Liver Cancer

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.

Can-Fite Updates On Status Of Phase II Advanced Liver Cancer Trial

Can-Fite Updates On Status Of Phase II Advanced Liver Cancer Trial

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with...

Can-Fite Reports On New Pre-Clinical Developments With Its NASH Drug Namodenoson

Can-Fite Reports On New Pre-Clinical Developments With Its NASH Drug Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today provided an update on new pre-clinical data supporting the...

Can-Fite Reports First Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite Reports First Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the three months...

Can-Fite's Piclidenoson Mechanism Of Action In Psoriasis Published In 'Journal Of Immunology Research'

Can-Fite's Piclidenoson Mechanism Of Action In Psoriasis Published In 'Journal Of Immunology Research'

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced the publication of a paper entitled "Inhibition of...

Can-Fite To Present At The MicroCap Conference

Can-Fite To Present At The MicroCap Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite Reports 2017 Financial Results & Provides Clinical Update

Can-Fite Reports 2017 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced...

Can-Fite To Present At The NASH 2nd Annual H.C. Wainwright Investor Conference

Can-Fite To Present At The NASH 2nd Annual H.C. Wainwright Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced...

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has...

Can-Fite To Participate In Panel Discussions On Latest Drug Developments In NASH At The 30th Annual ROTH Conference

Can-Fite To Participate In Panel Discussions On Latest Drug Developments In NASH At The 30th Annual ROTH Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite To Present At The Inaugural LD Micro Virtual Conference

Can-Fite To Present At The Inaugural LD Micro Virtual Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an...

Can Fite Announces The Submission Of Safety Reports For Piclidenoson And Namodenoson To FDA And Other Regulatory Authorities Showing Favorable Safety Profile

Can Fite Announces The Submission Of Safety Reports For Piclidenoson And Namodenoson To FDA And Other Regulatory Authorities Showing Favorable Safety Profile

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it...

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting A Novel Anti-NASH Mechanism Of Action For Namodenoson

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting A Novel Anti-NASH Mechanism Of Action For Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, announced today that...

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its...

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

TheStreet Quant Rating: D (Sell)